# Earnings Validation Framework - Feb 2026

**Portfolio:** 5 posiciones (â‚¬4,200 invested, 42%), cash â‚¬5,800 (58%)
**Periodo:** Feb 1 - Feb 26, 2026
**Objetivo:** Validar thesis de las 5 posiciones actuales post-compra

---

## Resumen Ejecutivo

**Â¿Por quÃ© este framework?**

Earnings season Feb-Mar 2026 es la **primera validaciÃ³n** de las 5 posiciones compradas en enero. Necesitamos verificar que las thesis estÃ¡n intactas y decidir HOLD/ADD/TRIM/SELL **ANTES** de continuar portfolio construction.

**Value investing = Buy right, hold IF thesis intact, sell IF thesis breaks.**

Este framework define:
- âœ… MÃ©tricas crÃ­ticas a verificar
- âœ… Triggers objetivos HOLD/ADD/TRIM/SELL
- âœ… Criterios invalidaciÃ³n thesis
- âœ… Checklist post-earnings para cada posiciÃ³n

**Decisiones se toman DESPUÃ‰S de earnings, NO antes.**

---

## Calendario Earnings

| Fecha | Ticker | Empresa | % Portfolio | ValidaciÃ³n |
|-------|--------|---------|-------------|------------|
| **Feb 1** | ENEL.MI | Enel SpA | 6% | [ENEL_feb2026.md](ENEL_feb2026.md) |
| **Feb 3** | PFE | Pfizer Inc. | 5% | [PFE_feb2026.md](PFE_feb2026.md) |
| **Feb 5** | ALL | Allstate Corp. | 4% | [ALL_feb2026.md](ALL_feb2026.md) |
| **Feb 5** | SHEL.L | Shell plc | 15% | [SHEL_feb2026.md](SHEL_feb2026.md) |
| **Feb 26** | DTE.DE | Deutsche Telekom | 12% | [DTE_feb2026.md](DTE_feb2026.md) |

**Total:** â‚¬4,200 (42% portfolio) en validaciÃ³n

---

## Thesis Summary - Â¿QuÃ© Estamos Validando?

### 1. Enel (â‚¬600, 6%) - Feb 1

**Thesis:** Utility EU #1 barata (P/E 9.6x) por riesgo LATAM overpriced, CEO Cattaneo ejecutando excelente

**Validar:**
- âœ… Net income â‚¬6.5-7.0B â†’ Thesis intacta
- âœ… Brasil concession progress â†’ Riesgo LATAM manejable
- âœ… Guidance 2026 fuerte â†’ Cattaneo execution continÃºa

**DecisiÃ³n esperada:** HOLD (mÃ¡s probable) o ADD â‚¬200-300 si beat + Brasil positivo

**Key risk:** Brasil concession perdida = SELL signal

---

### 2. Pfizer (â‚¬500, 5%) - Feb 3

**Thesis:** Big pharma yield 6.84% cushion defensivo, pipeline obesity/oncology repone patent cliff, P/E 14.8x barato

**Validar:**
- âœ… Dividend $1.72 maintained â†’ CRITICAL, 50% de thesis
- âœ… Pipeline progress (Metsera GLP-1, ADCs) â†’ Execution on track
- âœ… Guidance 2026 $59.5-62.5B revenue â†’ TransiciÃ³n post-COVID OK

**DecisiÃ³n esperada:** HOLD (mÃ¡s probable) o ADD si Metsera Phase 2 data positiva

**Key risk:** Dividend CUT = SELL signal inmediato (yield trap)

---

### 3. Allstate (â‚¬400, 4%) - Feb 5

**Thesis:** P/E 6.3x (72% mÃ¡s barato Admiral UK), ROE 37%, combined ratio 80%, turnaround completado

**Validar:**
- âœ… Combined ratio Q4 <92% â†’ Turnaround sostenible
- âœ… ROE annual >30% â†’ Execution exceptional no fluke
- âœ… Guidance 2026 mid-90s combined ratio â†’ Realistic

**DecisiÃ³n esperada:** HOLD o ADD â‚¬300-400 si combined ratio <88% (beat)

**Key risk:** Combined ratio >100% = underwriting loss, SELL signal

---

### 4. Shell (â‚¬1,500, 15%) - Feb 5

**Thesis:** FCF $40B/aÃ±o, P/FCF 7x, buybacks $3.5B/trim, LNG moat, hedge geopolÃ­tico IrÃ¡n

**Validar:**
- âœ… FCF FY2025 $38-42B â†’ Cash machine funcionando
- âœ… Buyback $3.5B Q4 (16 trimestres consecutivos >$3B) â†’ Commitment intact
- âœ… LNG business growing +3-5% â†’ Moat validado

**DecisiÃ³n esperada:** TRIM 30% (â‚¬1,500 â†’ â‚¬1,050) si thesis validated = rebalanceo oversized 15% â†’ 10%

**Key risk:** Buyback cortado <$3B = red flag management discipline

---

### 5. DTE (â‚¬1,200, 12%) - Feb 26

**Thesis:** P/E 11x con ROE 20%, T-Mobile US hidden value 60%+ DTE, guidance raised 3x 2025, FCF â‚¬20-30B

**Validar:**
- âœ… FY2025 earnings meet/beat (guidance 3x raised materializa)
- âœ… T-Mobile US contribution strong â†’ Hidden value intact
- âœ… Guidance 2026 + EPS â‚¬2.50 2027 reconfirmed â†’ Momentum continÃºa

**DecisiÃ³n esperada:** TRIM 40-50% (â‚¬1,200 â†’ â‚¬600-720) si thesis validated = rebalanceo oversized 12% â†’ 6%

**Key risk:** T-Mobile US market cap <$170B + guidance cut = thesis breaks

---

## Posibles Outcomes - Escenarios Portfolio

### Escenario A: 4-5 posiciones VALIDAN thesis (Probability: 60%)

**Resultado:**
- Portfolio execution STRONG
- 5/5 posiciones compradas correctamente
- Defensive (Enel, Pfizer, Allstate): 15% validado
- Cyclical (Shell, DTE): 27% validado

**Acciones:**
1. **HOLD:** Enel, Pfizer, Allstate (thesis intactas)
2. **TRIM:** Shell 30% (â‚¬1,500 â†’ â‚¬1,050) + DTE 40% (â‚¬1,200 â†’ â‚¬720)
   - RazÃ³n: Rebalanceo oversized 15%/12% â†’ 10%/7% target
   - Libera: â‚¬450 (Shell) + â‚¬480 (DTE) = â‚¬930 cash
3. **Cash post-rebalanceo:** â‚¬5,800 + â‚¬930 = â‚¬6,730 (67%)

**Siguiente:**
- Esperar correcciÃ³n defensive Q2 2026 (REITs, Medtech caen 10-20%)
- O evaluar cyclical mejor timing (RIO si iron ore $80-85)
- Validar CVS Q4 earnings 11-feb (si beat â†’ ADD â‚¬300 opportunistic)

---

### Escenario B: 3 posiciones VALIDAN, 2 MISS (Probability: 30%)

**Resultado:**
- Portfolio MIXED
- Algunas thesis dÃ©biles, necesitan acciÃ³n

**Acciones:**
1. **HOLD:** Posiciones que validaron
2. **TRIM 50%:** Posiciones que missed (reduce exposure, no panic sell)
3. **Libera cash:** ~â‚¬400-600 para mejores oportunidades

**Siguiente:**
- Re-evaluar posiciones trimmed en Q1 2026 earnings
- Focus defensive gap 20-25% si value aparece

---

### Escenario C: 3+ posiciones MISS/SELL (Probability: 10%)

**Resultado:**
- Portfolio WEAKNESS generalizada
- MÃºltiples thesis invalidadas

**Acciones:**
1. **SELL:** Posiciones con thesis invalidada (dividend cuts, guidance disasters)
2. **TRIM heavy:** Posiciones restantes
3. **Cash aumenta:** 58% â†’ 75-80%

**Siguiente:**
- Re-evaluar estrategia portfolio construction
- Esperar Q1 2026 earnings season antes de reinvertir
- Considerar si mercado entrÃ³ correcciÃ³n (portfolio reflejo macro)

---

## Portfolio Impact Analysis

### ConfiguraciÃ³n Actual (Pre-Earnings)

| CategorÃ­a | Actual | Target | Gap |
|-----------|--------|--------|-----|
| **Defensive** | 15% | 35-40% | -20-25% |
| **Cyclical** | 27% | 45-50% | -18-23% |
| **Cash** | 58% | 10-15% | +43-48% |
| **Posiciones** | 5 | 16-20 | -11-15 |

**Problemas:**
- âš ï¸ Shell oversized 15% (target 6% cyclical)
- âš ï¸ DTE oversized 12% (target 5-6% cyclical)
- âš ï¸ Cash muy alto 58% (target 10-15%)

### ConfiguraciÃ³n Post-Earnings (Escenario A)

**Si TRIM Shell + DTE:**

| CategorÃ­a | Post-Trim | Target | Gap |
|-----------|-----------|--------|-----|
| **Defensive** | 15% | 35-40% | -20-25% (sin cambio) |
| **Cyclical** | 17% | 45-50% | -28-33% (empeora) |
| **Cash** | 67% | 10-15% | +52-57% (aumenta) |

**Trade-off:**
- âœ… Shell + DTE sizing apropiado (10% + 7% = OK)
- âš ï¸ Cyclical gap aumenta (necesitamos aÃ±adir mÃ¡s cyclical despuÃ©s)
- âš ï¸ Cash aumenta (necesitamos invertir defensive gap)

**ConclusiÃ³n:** TRIM es correcto portfolio structure PERO necesitamos plan invertir â‚¬930 liberado.

**Plan post-TRIM:**
1. **Prioridad 1:** Cerrar gap defensive 20-25%
   - Esperar correcciÃ³n Q2 2026 (REITs, Medtech -10-20%)
   - O CVS Q4 beat 11-feb â†’ ADD â‚¬300 (opportunistic, NO defensive)
2. **Prioridad 2:** Re-evaluar cyclical timing
   - RIO watchlist si iron ore $80-85, precio $50-52
   - Materials sector post-correcciÃ³n Q2-Q3 2026

---

## Rebalancing Triggers - Decisiones Predefinidas

### TRIM Shell + DTE (Portfolio Structure)

**Condiciones:**
- âœ… Ambos earnings MEET o BEAT (thesis validated)
- âœ… Portfolio oversized: Shell 15% (target 6%), DTE 12% (target 5-6%)
- âœ… Disciplina V2.0: Trim winners, maintain structure

**AcciÃ³n:**
- Shell: â‚¬1,500 â†’ â‚¬1,050 (TRIM 30%, 15% â†’ 10%)
- DTE: â‚¬1,200 â†’ â‚¬720 (TRIM 40%, 12% â†’ 7%)
- Libera: â‚¬930 cash

**RazÃ³n:** Value investing â‰  buy and hold forever. Rebalanceo mantiene portfolio structure optimal.

**Timing:** Ejecutar despuÃ©s de validar earnings Feb 5 (Shell) + Feb 26 (DTE)

---

### ADD Posiciones (Cierre Gap Defensive)

**Condiciones ADD individual:**
- âœ… Earnings BEAT significativo
- âœ… Thesis fortalece (riesgo reduce, upside aumenta)
- âœ… Margen seguridad aumenta >30%
- âœ… P/E post-earnings sigue barato

**Posibles ADD:**
- Enel: +â‚¬200-300 (6% â†’ 9%) si Brasil positivo + beat
- Pfizer: +â‚¬200-300 (5% â†’ 7-8%) si Metsera Phase 2 data positiva
- Allstate: +â‚¬300-400 (4% â†’ 7-8%) si combined ratio <88%

**Portfolio impact ADD mÃ¡ximo (â‚¬700-1000):**
- Defensive: 15% â†’ 22-25% (cierra gap parcialmente)
- Cash: 58% â†’ 51-55% (OK >5%)

**DecisiÃ³n:** ADD solo si earnings exceptional + margen seguridad >30% post-beat.

---

## Checklist Master - Earnings Season

### Pre-Earnings (Ahora - Jan 31)

- [x] Crear framework validaciÃ³n 5 posiciones
- [x] Definir mÃ©tricas crÃ­ticas cada posiciÃ³n
- [x] Establecer triggers HOLD/ADD/TRIM/SELL
- [ ] Revisar calendario earnings (confirmar fechas exactas)
- [ ] Configurar alertas earnings release (eToro, Yahoo Finance, IR sites)

### Durante Earnings (Feb 1-26)

**Para cada earnings release:**

1. **DÃ­a earnings (T+0):**
   - [ ] Leer earnings release completo
   - [ ] Verificar mÃ©tricas crÃ­ticas framework
   - [ ] Escuchar earnings call (o leer transcript T+1)

2. **Post-earnings (T+1 a T+2):**
   - [ ] Leer 3-5 analyst notes
   - [ ] Verificar reacciÃ³n mercado (Â¿justificada?)
   - [ ] Actualizar thesis/research/{TICKER}/thesis.md
   - [ ] Decidir acciÃ³n: HOLD / ADD / TRIM / SELL

3. **Ejecutar decisiÃ³n (T+2 a T+3):**
   - [ ] Si HOLD: Documentar validaciÃ³n
   - [ ] Si ADD/TRIM/SELL: Ejecutar en eToro
   - [ ] Actualizar portfolio/current.yaml
   - [ ] Calcular impacto portfolio structure
   - [ ] Documentar en journal/decisions/

### Post-Earnings Season (Feb 27+)

- [ ] Portfolio review completo 5/5 posiciones
- [ ] Calcular: % posiciones validadas vs invalidadas
- [ ] Actualizar state/system.yaml con results
- [ ] Decidir siguiente focus:
  - Si 4-5 validadas: Continuar portfolio construction (defensive gap)
  - Si 2-3 validadas: Esperar Q1 2026 earnings re-validar
  - Si 0-2 validadas: Re-evaluar estrategia completa

---

## MÃ©tricas de Ã‰xito - Â¿CÃ³mo Evaluar Este Framework?

### Ã‰xito = Decisiones Objetivas Basadas en Datos

**NO Ã©xito:**
- "Aguantar porque bajÃ³" (fear)
- "Vender porque subiÃ³" (greed)
- "No hacer nada" (inaction bias)

**SÃ Ã©xito:**
- Thesis validada â†’ HOLD (discipline)
- Thesis fortalece â†’ ADD (conviction)
- Thesis debilita â†’ TRIM (risk management)
- Thesis invalida â†’ SELL (cut losses)

### MÃ©tricas Post-Earnings Season

| MÃ©trica | Target | Actual |
|---------|--------|--------|
| % posiciones thesis validada | >60% (3/5) | TBD |
| % portfolio HOLD post-earnings | >70% | TBD |
| % portfolio TRIM/SELL | <30% | TBD |
| Decisiones ejecutadas vs plan | 100% | TBD |
| Tiempo decisiÃ³n post-earnings | <3 dÃ­as | TBD |

**Review Feb 28:** Documentar lessons learned de cada decisiÃ³n.

---

## Lessons Framework - Â¿QuÃ© Aprender?

### De cada earnings, documentar:

1. **Surprise:** Â¿QuÃ© fue diferente vs expectativas?
2. **Thesis:** Â¿Validada, fortalecida, debilitada, invalidada?
3. **Management:** Â¿Execution cumpliÃ³ promesas?
4. **DecisiÃ³n:** Â¿HOLD/ADD/TRIM/SELL fue correcta en retrospectiva?
5. **Mejora:** Â¿QuÃ© habrÃ­a hecho diferente con hindsight?

**Guardar en:** journal/decisions/{YYYY-MM-DD}_earnings_{TICKER}.md

---

## Contacto con Usuario

**ComunicaciÃ³n earnings:**

DespuÃ©s de cada earnings, informar usuario brevemente:

```
ðŸ“Š {TICKER} Q4 2025 Earnings - {BEAT/MEET/MISS}

Resultados clave:
â€¢ {MÃ©trica 1}: {Valor} {âœ…/âš ï¸/âŒ}
â€¢ {MÃ©trica 2}: {Valor} {âœ…/âš ï¸/âŒ}
â€¢ {MÃ©trica 3}: {Valor} {âœ…/âš ï¸/âŒ}

DecisiÃ³n: {HOLD / ADD â‚¬X / TRIM Y% / SELL}
RazÃ³n: {1 frase clara}

{Si HOLD: No requiere acciÃ³n}
{Si ADD/TRIM/SELL: Ejecuta en eToro y actualiza portfolio/current.yaml}

Thesis: {VALIDADA / FORTALECIDA / DEBILITADA / INVALIDADA}
```

**Portfolio review final (Feb 28):**

```
ðŸ“ˆ PORTFOLIO REVIEW POST-EARNINGS SEASON

Posiciones validadas: X/5
Acciones tomadas:
â€¢ HOLD: {list}
â€¢ ADD: {list + amounts}
â€¢ TRIM: {list + %}
â€¢ SELL: {list}

Portfolio nuevo:
â€¢ Defensive: X% (target 35-40%)
â€¢ Cyclical: X% (target 45-50%)
â€¢ Cash: X% (target 10-15%)
â€¢ Posiciones: X (target 16-20)

PrÃ³ximos pasos:
{Plan accionable segÃºn results}
```

---

**FRAMEWORK CREADO:** 2026-01-30
**VALIDACIONES:** 5 archivos individuales + README master
**PRÃ“XIMO EARNINGS:** Feb 1, 2026 (Enel) - 2 dÃ­as
**REVIEW FRAMEWORK:** Feb 28, 2026 (post-todos earnings)